(Q42169332)

17 October 2017

title

Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase (English)

1 reference

17 October 2017

3

1 reference

17 October 2017

4

1 reference

17 October 2017

5

Vern L Schramm

1 reference

17 October 2017

2

Peter C Tyler

1 reference

17 October 2017

1

Andrzej Lewandowicz

1 reference

17 October 2017

language of work or name

English

0 references

publication date

3 July 2003

1 reference

Journal of Biological Chemistry

17 October 2017

published in

1 reference

17 October 2017

volume

278

1 reference

17 October 2017

issue

34

1 reference

17 October 2017

page(s)

31465-31468

1 reference

Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Deoxyguanosine Triphosphate as a Possible Toxic Metabolite in the Immunodeficiency Associated with Purine Nucleoside Phosphorylase Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Transition state analogue inhibitors of purine nucleoside phosphorylase from Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Imino-sugar-based nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Over-the-barrier transition state analogues and crystal structure with Mycobacterium tuberculosis purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Ionic states of substrates and transition state analogues at the catalytic sites of N-ribosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Inhibition of uracil DNA glycosylase by an oxacarbenium ion mimic

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Synthesis of Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase and N-Riboside Hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.C300259200

21 January 2018

Identifiers

DOI

10.1074/JBC.C300259200

1 reference

17 October 2017

1 reference